Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Poynard

Showing results (291-300 of 324) with videos related to

Pageof 33
Sort By:
Alimentary Pharmacology & Therapeutics|February 22, 2007
Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentationT Poynard, P Halfon, L Castera, et al.
Gastroenterologie Clinique Et Biologique|January 1, 1991
[Randomized double-blind trial with a liquid suspension of alginate for the treatment of pyrosis]B Filoche, E Carteret, B Couzigou, et al.
Journal of Hepatology|April 27, 2000
Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroidsJ Taïeb, P Mathurin, C Elbim, et al.
Clinical and Experimental Immunology|August 11, 1998
No evidence for abnormal immune activation in peripheral blood T cells in patients with hepatitis C virus (HCV) infection with or without cryoglobulinaemia. Multivirc GroupP Cacoub, L Musset, P Hausfater, et al.
Lancet (London, England)|November 10, 1998
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)T Poynard, P Marcellin, S S Lee, et al.
Alimentary Pharmacology & Therapeutics|September 5, 2007
Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis CR Morra, M Munteanu, P Bedossa, et al.
Gut|January 5, 2002
Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot studyR Moreau, T Asselah, B Condat, et al.
British Journal of Cancer|April 16, 2002
Gene expression profiles of bladder cancers: evidence for a striking effect of in vitro cell models on gene patternsV Dangles, V Lazar, P Validire, et al.
Gastroenterologie Clinique Et Biologique|December 17, 2008
Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 updateT Poynard, M Muntenau, R Morra, et al.
Annales De Biologie Clinique|June 14, 2005
[Results transferability on RXL, ARX, X-Pand, BN2 (Dade Behring) and modular DP (Roche Diagnostics) analysers: application to component assays of fibrotest and Actitest]F Imbert-Bismut, D Messous, A Raoult, et al.
Pageof 33

Showing results (291-300 of 324) with videos related to

Sort By:
Pageof 33
Alimentary Pharmacology & Therapeutics|February 22, 2007
Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentationT Poynard, P Halfon, L Castera, et al.
Gastroenterologie Clinique Et Biologique|January 1, 1991
[Randomized double-blind trial with a liquid suspension of alginate for the treatment of pyrosis]B Filoche, E Carteret, B Couzigou, et al.
Journal of Hepatology|April 27, 2000
Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroidsJ Taïeb, P Mathurin, C Elbim, et al.
Clinical and Experimental Immunology|August 11, 1998
No evidence for abnormal immune activation in peripheral blood T cells in patients with hepatitis C virus (HCV) infection with or without cryoglobulinaemia. Multivirc GroupP Cacoub, L Musset, P Hausfater, et al.
Lancet (London, England)|November 10, 1998
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)T Poynard, P Marcellin, S S Lee, et al.
Alimentary Pharmacology & Therapeutics|September 5, 2007
Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis CR Morra, M Munteanu, P Bedossa, et al.
Gut|January 5, 2002
Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot studyR Moreau, T Asselah, B Condat, et al.
British Journal of Cancer|April 16, 2002
Gene expression profiles of bladder cancers: evidence for a striking effect of in vitro cell models on gene patternsV Dangles, V Lazar, P Validire, et al.
Gastroenterologie Clinique Et Biologique|December 17, 2008
Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 updateT Poynard, M Muntenau, R Morra, et al.
Annales De Biologie Clinique|June 14, 2005
[Results transferability on RXL, ARX, X-Pand, BN2 (Dade Behring) and modular DP (Roche Diagnostics) analysers: application to component assays of fibrotest and Actitest]F Imbert-Bismut, D Messous, A Raoult, et al.
Pageof 33